EMA will present its opinion on Astrazeneca vaccine this afternoon

The European Medicines Agency EMA will present an opinion on the Astrazeneca vaccine at 4 p.m. The drug has often been in the news in recent days due to possible side effects.

A number of people experienced a rare combination of thrombosis and a reduced platelet count. It is not clear whether the Astrazeneca vaccine is the cause of this. Yesterday Marco Cavaleri, head of vaccination strategy at EMA, said that there is most likely a link between the possible side effects and the vaccine, adding that the benefits outweigh the disadvantages. The EEA has not yet taken an official position.

The EMA has reviewed the possible side effects of the vaccine in recent days. Several dozen people in Europe suffered from the rare combination shortly after receiving the Astrazeneca vaccine. In the Netherlands, side effects centre Lareb received five such reports. In total, more than 400,000 pricks with the vaccine have been put in our country.

In three women, the blood clots got into the lungs. A woman died of it. Another woman also had a cerebral hemorrhage. The Netherlands decided on Friday to temporarily stop vaccination with AstraZeneca for people under 60 years of age. At least until today.

Experts do not understand anything about temporary stop

Thrombosis experts said last weekend not to understand that decision. According to them, temporary cessation is a greater risk to public health, despite reports of blood clots. They say the ministry did not consult the experts prior to the decision to stop.

They indicate that the relationship between the Astrazeneca vaccine and the complex clinical picture has not yet been established. But if there is a connection, they argue, then the risk of death after a prick is probably very small.

In mid-March, the Netherlands also temporarily stopped taking the vaccine after reports of thrombotic symptoms abroad. The EMA stated shortly thereafter that there is no apparent link between the Astrazeneca vaccine and thrombosis in the general sense. On rare and severe thrombosed cases, EMA then said that a link to the vaccine was not established, but could not be ruled out either.